Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 39,225
  • Shares Outstanding, K 7,250
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,312 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.13 +5.46%
on 02/17/26
7.14 -24.23%
on 01/28/26
-0.65 (-10.73%)
since 01/20/26
3-Month
5.13 +5.46%
on 02/17/26
18.00 -69.94%
on 12/03/25
-4.82 (-47.12%)
since 11/20/25
52-Week
5.13 +5.46%
on 02/17/26
135.00 -95.99%
on 04/24/25
-66.39 (-92.47%)
since 02/20/25

Most Recent Stories

More News
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology...

BCT.TO : 5.41 (-4.08%)
BCTXW : 0.0028 (-53.33%)
BCTXZ : 0.1675 (+15.28%)
BCTXL : 1.1000 (+10.00%)
BCTX : 3.92 (-5.08%)
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Fifth consecutive positive DSMB...

BCT.TO : 5.41 (-4.08%)
BCTXW : 0.0028 (-53.33%)
BCTXZ : 0.1675 (+15.28%)
BCTXL : 1.1000 (+10.00%)
BCTX : 3.92 (-5.08%)
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT...

BCT.TO : 5.41 (-4.08%)
BCTXW : 0.0028 (-53.33%)
BCTXZ : 0.1675 (+15.28%)
BCTXL : 1.1000 (+10.00%)
BCTX : 3.92 (-5.08%)
Stocks in play: BriaCell Therapeutics Corp.

Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks ...

BCT.TO : 5.41 (-4.08%)
Stocks in play: BriaCell Therapeutics Corp.

Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks ...

BCT.TO : 5.41 (-4.08%)
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022   remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations ...

BCT.TO : 5.41 (-4.08%)
BCTXW : 0.0028 (-53.33%)
BCTXZ : 0.1675 (+15.28%)
BCTXL : 1.1000 (+10.00%)
BCTX : 3.92 (-5.08%)
Upcoming Meeting Dates - January 19, 2026

Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

CPS.VN : 0.090 (unch)
MILI.CN : 0.3900 (-1.27%)
PRCG.CN : 0.2450 (unch)
MBX.TO : 0.2300 (-4.17%)
MGA.TO : 0.72 (+2.86%)
BCM.VN : 1.030 (+14.44%)
IN.VN : 0.045 (unch)
COS.VN : 0.085 (+6.25%)
AIS.VN : 0.070 (unch)
NGY.VN : 0.015 (unch)
GGR.CN : 0.2500 (-12.28%)
HUNT.CN : 0.0700 (unch)
BriaCell Therapeutics Announces Closing of US$30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BCT.TO : 5.41 (-4.08%)
BCTXW : 0.0028 (-53.33%)
BCTXZ : 0.1675 (+15.28%)
BCTXL : 1.1000 (+10.00%)
BCTX : 3.92 (-5.08%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.9640 (-3.60%)
BCT.TO : 5.41 (-4.08%)
ACRV : 1.5300 (-3.16%)
LLY : 1,009.52 (-1.34%)
BCTX : 3.92 (-5.08%)
GLSI : 24.06 (-3.49%)
CATX : 5.65 (unch)
BriaCell Therapeutics Announces Pricing of $30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BCT.TO : 5.41 (-4.08%)
BCTXW : 0.0028 (-53.33%)
BCTXZ : 0.1675 (+15.28%)
BCTXL : 1.1000 (+10.00%)
BCTX : 3.92 (-5.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes...

See More

Key Turning Points

3rd Resistance Point 5.90
2nd Resistance Point 5.77
1st Resistance Point 5.59
Last Price 5.41
1st Support Level 5.28
2nd Support Level 5.15
3rd Support Level 4.97

See More

52-Week High 135.00
Fibonacci 61.8% 85.39
Fibonacci 50% 70.07
Fibonacci 38.2% 54.74
Last Price 5.41
52-Week Low 5.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar